Publications
322
Citations
5,303
Est. group size
~80
Recurring co-author estimate
Active years
27
Publishing since 2000
Lapo Alinari's research focuses on blood cancers, particularly lymphomas and chronic lymphocytic leukemia (CLL), with an emphasis on finding new drug targets and testing experimental therapies. Recent work includes studying how certain genes (like SOX11 and PAX5) affect drug resistance in mantle cell lymphoma, developing engineered immune cells (CAR-T and CAR-NK cells) to attack cancer cells, and testing new drugs (such as SUMO-pathway inhibitors) that may help the immune system fight cancer more effectively. This work combines laboratory research on cancer biology with early clinical trials of new treatments.
Publication output grew substantially from 2017 through 2023, followed by a leveling off at a high rate of activity in 2024-2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- SOX11 modulates BCR signaling through the PAX5/CD19 axis for therapeutic targeting in BTK-resistant mantle cell lymphoma
Blood Advances · 2025
- 252 Development of anti-CD5 CAR NK cells that target malignant T cells while sparing normal T cells
Regular and Young Investigator Award Abstracts · 2025
- Figure S3 from T Cell–intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic Leukemia
2025
- Table S2 from T Cell–intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic Leukemia
2025
- Trials in progress - A phase II study of pemigatinib in patients with relapsed or refractory B-cell non-Hodgkin lymphomas (PERFORM)
Blood · 2025
- Inhibition of SRC-3 as a potential therapeutic strategy for aggressive mantle cell lymphoma
PLoS ONE · 2024
- Novel Insights into SOX11 Modulation of BCR Signaling and Targeting of BTK Resistance
Blood · 2024
- Table S2 from T cell-intrinsic immunomodulatory effects of TAK-981 (subasumstat), a SUMO-activating enzyme inhibitor, in chronic lymphocytic leukemia
2024
- Table S1 from T cell-intrinsic immunomodulatory effects of TAK-981 (subasumstat), a SUMO-activating enzyme inhibitor, in chronic lymphocytic leukemia
2024
- Figure S1 from T cell-intrinsic immunomodulatory effects of TAK-981 (subasumstat), a SUMO-activating enzyme inhibitor, in chronic lymphocytic leukemia
2024
- Figure S2 from T cell-intrinsic immunomodulatory effects of TAK-981 (subasumstat), a SUMO-activating enzyme inhibitor, in chronic lymphocytic leukemia
2024
- Data from T cell-intrinsic immunomodulatory effects of TAK-981 (subasumstat), a SUMO-activating enzyme inhibitor, in chronic lymphocytic leukemia
2024
- Figure S4 from T cell-intrinsic immunomodulatory effects of TAK-981 (subasumstat), a SUMO-activating enzyme inhibitor, in chronic lymphocytic leukemia
2024
- Figure S2 from T cell-intrinsic immunomodulatory effects of TAK-981 (subasumstat), a SUMO-activating enzyme inhibitor, in chronic lymphocytic leukemia
2024
- Supplementary Data Methods from T cell-intrinsic immunomodulatory effects of TAK-981 (subasumstat), a SUMO-activating enzyme inhibitor, in chronic lymphocytic leukemia
2024
- Blood×44
- Blood Advances×9
- Hematological Oncology×6
- Transplantation and Cellular Therapy×5
- Journal of Hematology & Oncology×4
- Kami J. Maddocks
Medicine · The Ohio State University
- David A. Bond
Medicine · The Ohio State University
- Beth Christian
Medicine · The Ohio State University
- Hui Yu
Medicine · The Ohio State University
- Zachary Braunstein
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile